Six translational health research centers across the globe have formed an alliance to advance the global international academic and/or not-for-profit drug development.
The alliance will also focus on commercializing network, thereby enhancing the rate of translating academic research into new medicines.
Founding organizations include The Centre for Drug Research and Development (CDRD), Canada, Lead Discovery Center (LDC), Germany, The Scripps Research Institute, Scripps Florida, US, The Centre for Drug Design and Discovery (CD3), KU Leuven R&D, Belgium, Medical Research Council Technology, UK and Cancer Research Technology, UK.
CDRD president and CEO Karimah Es Sabar said, "This Alliance will be a powerful vehicle in bringing such organizations together, leveraging one another's strengths, and ultimately making for a much more effective global translational research environment."
The member organizations will work together by the means of the alliance to convert early stage technology into new therapies, by sharing their practices, skill and resources.
